瘤向氧酸纳米颗粒用于通过激活癌症中线粒DNA-pyroptosis通路来重塑瘤免疫微环境 (TIME)
Yuxuan Yang1, Jia Yang1,2, Nan Zhu1
1Department of General Surgery, Nanfang Hospital, Southern medical University, Guangzhou, 510515, China.
Journal of nanobiotechnology
|December 7, 2023
概括
新型纳米药物诱导细胞灭绝,一种被编程的细胞死亡,将"冷"瘤转化为"热"瘤. 这增强了抗瘤免疫力,通过触发强烈的炎症反应,使瘤更容易对免疫疗法作出反应.
科学领域:
- 生物医学工程 生物医学工程
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 免疫疗法对固体瘤有希望,但在许多患者中有效性有限.
- 将不响应的"冷"瘤转化为免疫响应的"热"瘤对于改善癌症治疗结果至关重要.
- 作为一种被编程细胞死亡途径的灭,可以消除瘤细胞并启动抗瘤免疫反应,这表明它有可能提高免疫治疗的疗效.
研究的目的:
- 开发能够诱导热的新型纳米药物,以改善癌症免疫疗法.
- 构建瘤向纳米颗粒 (CS-HAP@ATO NPs) 载有阿托瓦斯塔丁 (ATO) 在酸盐 (CS) 修饰的酸 (HAP) 纳米颗粒上.
- 研究这些纳米颗粒诱导热和增强抗瘤免疫力的机制.
主要方法:
- 地丁硫酸盐 (CS) 用于瘤细胞向,而氧酸盐 (HAP) 纳米颗粒在瘤微环境中释放离子 (Ca2+).
- 阿托瓦斯塔丁 (ATO) 破坏了线粒体功能,导致能量耗尽和线粒体膜透性增加.
- 这些纳米颗粒诱导了线粒体过载,反应性氧物种 (ROS) 生产,炎酶组合 (NLRP3),caspase-1激活和气体皮质D (GSDMD) 裂变,最终导致热亡.
主要成果:
- CS-HAP@ATO NPs有效地向瘤细胞,并通过涉及线粒体功能障碍和过载的级联诱导热.
- 诱导的热导致炎症媒介的释放,并增强了抗瘤免疫反应.
- 这一过程促进了炎酶激活,卡斯帕-1和GSDMD裂变,导致热细胞死亡和瘤免疫性增加.
结论:
- CS-HAP@ATO NPs在诱导热和使瘤对免疫治疗敏感方面是有效的.
- 这种纳米医学方法有可能将"冷"瘤转化为免疫学上"热"的瘤,从而提高治疗效率.
- 这项研究强调了诱导热的纳米药物在癌症治疗和免疫疗法增强中的治疗潜力.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
5.7K
相关概念视频
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
